Goepfert PA, Fu B, Chabanon AL, Bonaparte MI, et al. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study. Lancet Infect Dis 2021 Apr 19. pii: S1473-3099(21)00147.
PMID: 33887209